| Literature DB >> 19325834 |
Huafang Wang1,2, Yu Hu1,2, Tao Guo1,2, Heng Mei1, Xiaoping Zhang1, Wangqiang Sun3.
Abstract
To investigate a nuclear factor-kappa B decoy oligonucleotides strategy on the inhibition of tissue factor (TF) expression in cultured rat brain microvascular endothelial cells (BMECs) by polylactic acid (PLA) nanoparticles delivery system and to evaluate this new vector for in vitro gene therapy. Nanoparticles were formulated using poly D,L-polylactic acid with surface modifying by polysorbates 80. 3-[4,5-Dimethylthiazol-2,5-diphenyl-2H-tetrazolium bromide] (MTT) assays showed that PLA nanoparticles were not toxic to the cultured BMECs.The decoy oligonuceotides (ODNs) loaded within nanoparticles was 6 microg/mg, encapsulation efficacy was (60.5+/-1.5)%. It was observed by flow cytometry that the cellular uptake of nanoparticles depended on the time of incubation and the concentration of nanoparticles in the medium. And confocal microscopy demonstrated that nanoparticles localized mostly in the BMECs cytoplasm. The released decoy oligonuceotides (ODNs) uptaked by BMECs retained their biologic activity and led to reduced level of tissue factor expression as compared to control cultures. These findings offer a potential therapeutic strategy in the control of TF expression in BMECs in vitro and suggest that PLA nanoparticles may be appropriate as delivery vehicles for decoy strategy in the gene therapy of cerebral thrombosis.Entities:
Keywords: Tissue factor; decoy oligonucleotides; nanoparticles; nuclear factor-kappaB; polylactic acid
Year: 2008 PMID: 19325834 PMCID: PMC2635753 DOI: 10.3390/ijms9091851
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1.AFM image of PLA-NPs loading decoy ODNs.
Figure 2.Size distribution of SFNPs: — density distribution and cumulative distribution.
The cell growth inhibitory ratio of BMECs by PLA NPs (%)
| working concentration (μg/ml) | Incubation time
| |||||
|---|---|---|---|---|---|---|
| 30min | 1h | 2h | 4h | 8h | 16h | |
| 1 | 1.5±0.8 | 1.8±1.7 | 2.5±1.2 | 1.8±1.0 | 1.6±1.2 | 1.6±1.1 |
| 2 | 1.8±1.1 | 1.7±1.2 | 2.0±1.4 | 2.1±0.9 | 1.9±1.6 | 1.8±2.1 |
| 5 | 3.6±1.5 | 2.7±1.5 | 2.5±1.2 | 2.8±1.2 | 2.0±1.9 | 1.9±1.6 |
| 10 | 5.2±1.6 | 4.0±1.3 | 3.6±0.2 | 3.2±0.3 | 2.8±1.1 | 2.2±1.2 |
| 20 | 8.4±1.8 | 7.6±1.2 | 6.7±2.2 | 4.3±1.6 | 3.8±2.1 | 3.1±1.4 |
Comparison of cell growth inhibitory ratio between different working concentration in the same column of incubation time, p<0.05.
Figure 3.The efficiency of uptake of nanoparticles by BMECs in six varying groups. (1) blank PLA nanoparticles; (2) FITC labeled decoy ODNs in PBS; (3) mixture of decoy ODNs and PLA nanoparticles; (4) decoy ODNs-loaded nanoparticls in three varying concentrations (0.5, 2.5, and 5μM; in culture medium).
Figure 4.(A) Location of decoy-PLA nanoparticlesuptaked by BMECs in cytoplasma; (B) control cells were incubated with NPs without ODNs.
Figure 5.Expression of TF mRNA in BMECs stimulated by LPS exposed to different decoy-PLA nanoparticles. (1) blank PLA nanoparticles were added; (2) 0.5 μM; decoy ODNs in PBS were added; (3) PLA nanoparticles loading 0.5μM M-decoy were added; (4) PLA nanoparticles loading 0.5 μM NF-κB decoy ODNs were added; (5) mixture of decoy ODNs and PLA nanoparticles were added; (6) blank control:no nanoparticles were added; (7) BMECs without LPS stimulation.
Figure 6.The change of content of P65 in BMECs nuclear extracts by preincubation with decoy-PLA nanoparticles. (1) blank PLA nanoparticles; (2) 0.5μM decoy ODNs; (3) M-decoy loaded PLA nanoparticles with 0.5μM M-decoy; (4) decoy-PLA nanoparticles with 0.5 μM NF-κB decoy ODNs; (5) mixture of decoy ODNs and PLA nanoparticles; (6) blank control.